NASDAQ: GRFSGrifols Sa Stock
$6.39-0.09 (-1.39%)
Updated Apr 24, 2024
GRFS Price
$6.39
Fair Value Price
$0.84
Market Cap
$4.39B
52 Week Low
$5.30
52 Week High
$12.15
P/E
65.88x
P/B
0.7x
P/S
1.09x
PEG
0.08x
Dividend Yield
N/A
Revenue
$7.09B
Earnings
$65.91M
Gross Margin
37.8%
Operating Margin
10.61%
Profit Margin
0.9%
Debt to Equity
2.31
Operating Cash Flow
$231M
Beta
0.69
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A
GRFS Overview
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumfrom prevention, screening, diagnosis, and prognosis to disease and treatment monitoringto serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
Zen Score
–
Industry Average (43)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how GRFS scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GRFS ($6.39) is overvalued by 658.25% relative to our estimate of its Fair Value price of $0.84 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
GRFS ($6.39) is not significantly undervalued (658.25%) relative to our estimate of its Fair Value price of $0.84 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
GRFS ($6.39) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more GRFS due diligence checks available for Premium users.
Be the first to know about important GRFS news, forecast changes, insider trades & much more!
GRFS News
Valuation
GRFS fair value
Fair Value of GRFS stock based on Discounted Cash Flow (DCF)
Price
$6.39
Fair Value
$0.84
Overvalued by
658.25%
GRFS ($6.39) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GRFS ($6.39) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GRFS ($6.39) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GRFS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
65.88x
Industry
153.97x
Market
41.27x
GRFS is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
GRFS is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
GRFS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.7x
Industry
5.95x
GRFS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GRFS price to earnings growth (PEG)
For valuing profitable companies with growth potential
GRFS is good value based... subscribe to Premium to read more.
PEG Value Valuation
GRFS's financial health
Profit margin
Revenue
$7.3B
Net Income
$65.9M
Profit Margin
0.9%
GRFS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
GRFS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$23.8B
Liabilities
$15.0B
Debt to equity
2.31
GRFS's short-term assets ($6.94B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GRFS's long-term liabilities ($11.99B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GRFS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
GRFS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$231.4M
Investing
-$441.8M
Financing
$206.7M
GRFS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GRFS vs General Drug Manufacturer Stocks
Grifols Sa Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.